Literature DB >> 21931123

Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans.

Barry I Freedman1, Carl D Langefeld, Mariana Murea, Lijun Ma, James D Otvos, Jolyn Turner, Peter A Antinozzi, Jasmin Divers, Pamela J Hicks, Donald W Bowden, Michael V Rocco, John S Parks.   

Abstract

BACKGROUND: Coding variants in the apolipoprotein L1 gene (APOL1) are strongly associated with non-diabetic nephropathy in African Americans. ApoL1 proteins associate with high-density lipoprotein (HDL) particles in the circulation. Plasma HDL particle subclass concentrations were compared in 73 African Americans based on APOL1 genotypes to detect differences potentially contributing to renal disease.
METHODS: HDL subclass concentrations were measured using nuclear magnetic resonance spectroscopy in African American first-degree relatives of patients with non-diabetic end-stage renal disease. Participants had estimated glomerular filtration rates (GFRs) > 80 mL/min and lacked albuminuria. Additive effects of the number of APOL1 risk variants on natural logarithm-transformed HDL subclass concentrations were computed.
RESULTS: Participants were 58.9% female with mean ± SD age 47.2 ± 13.3 years and GFR 92.4 ± 18.8 mL/min. The numbers with 2, 1 and 0 APOL1 nephropathy risk variants, respectively, were 36, 17 and 20. Mean ± SD medium-sized HDL concentrations were significantly lower for each additional APOL1 risk variant (2 versus 1 versus 0 risk variants: 9.0 ± 5.6 versus 10.1 ± 5.5 versus 13.1 ± 8.2 μmol/L, respectively; P = 0.0222 unadjusted; P = 0.0162 triglyceride- and ancestry adjusted).
CONCLUSIONS: Lower medium-sized HDL subclass concentrations are present in African Americans based on increasing numbers of APOL1 nephropathy risk variants. Potential mechanistic roles of altered medium HDL concentrations on APOL1-associated renal microvascular diseases should be evaluated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21931123      PMCID: PMC3203631          DOI: 10.1093/ndt/gfr542

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  35 in total

1.  MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.

Authors:  Jeffrey B Kopp; Michael W Smith; George W Nelson; Randall C Johnson; Barry I Freedman; Donald W Bowden; Taras Oleksyk; Louise M McKenzie; Hiroshi Kajiyama; Tejinder S Ahuja; Jeffrey S Berns; William Briggs; Monique E Cho; Richard A Dart; Paul L Kimmel; Stephen M Korbet; Donna M Michel; Michele H Mokrzycki; Jeffrey R Schelling; Eric Simon; Howard Trachtman; David Vlahov; Cheryl A Winkler
Journal:  Nat Genet       Date:  2008-09-14       Impact factor: 38.330

2.  Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD.

Authors:  Barry I Freedman; Pamela J Hicks; Meredith A Bostrom; Mary E Comeau; Jasmin Divers; Anthony J Bleyer; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Carl D Langefeld; Donald W Bowden
Journal:  Nephrol Dial Transplant       Date:  2009-06-30       Impact factor: 5.992

3.  Mechanism of action of APOL1 in renal allograft survival (and Native CKD) remains unclear.

Authors:  D B Johnstone
Journal:  Am J Transplant       Date:  2011-08-03       Impact factor: 8.086

4.  Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans.

Authors:  Barry I Freedman; Pamela J Hicks; Meredith A Bostrom; Mary E Cunningham; Yongmei Liu; Jasmin Divers; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; Carl D Langefeld; Donald W Bowden
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

5.  Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1.

Authors:  Anny Mulya; Jeongmin Seo; Amanda L Brown; Abraham K Gebre; Elena Boudyguina; Gregory S Shelness; John S Parks
Journal:  J Lipid Res       Date:  2009-09-18       Impact factor: 5.922

6.  Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.

Authors:  Lawrence J Appel; Jackson T Wright; Tom Greene; John W Kusek; Julia B Lewis; Xuelei Wang; Michael S Lipkowitz; Keith C Norris; George L Bakris; Mahboob Rahman; Gabriel Contreras; Stephen G Rostand; Joel D Kopple; Francis B Gabbai; Gerald I Schulman; Jennifer J Gassman; Jeanne Charleston; Lawrence Y Agodoa
Journal:  Arch Intern Med       Date:  2008-04-28

7.  MYH9 is associated with nondiabetic end-stage renal disease in African Americans.

Authors:  W H Linda Kao; Michael J Klag; Lucy A Meoni; David Reich; Yvette Berthier-Schaad; Man Li; Josef Coresh; Nick Patterson; Arti Tandon; Neil R Powe; Nancy E Fink; John H Sadler; Matthew R Weir; Hanna E Abboud; Sharon G Adler; Jasmin Divers; Sudha K Iyengar; Barry I Freedman; Paul L Kimmel; William C Knowler; Orly F Kohn; Kristopher Kramp; David J Leehey; Susanne B Nicholas; Madeleine V Pahl; Jeffrey R Schelling; John R Sedor; Denyse Thornley-Brown; Cheryl A Winkler; Michael W Smith; Rulan S Parekh
Journal:  Nat Genet       Date:  2008-09-14       Impact factor: 38.330

8.  Exploration of the utility of ancestry informative markers for genetic association studies of African Americans with type 2 diabetes and end stage renal disease.

Authors:  Keith L Keene; Josyf C Mychaleckyj; Tennille S Leak; Shelly G Smith; Peter S Perlegas; Jasmin Divers; Carl D Langefeld; Barry I Freedman; Donald W Bowden; Michèle M Sale
Journal:  Hum Genet       Date:  2008-07-25       Impact factor: 4.132

9.  An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma.

Authors:  Olof Axler; Josefin Ahnström; Björn Dahlbäck
Journal:  J Lipid Res       Date:  2007-05-25       Impact factor: 5.922

10.  Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study.

Authors:  Barry I Freedman; Jeffrey B Kopp; Cheryl A Winkler; George W Nelson; D C Rao; John H Eckfeldt; Mark F Leppert; Pamela J Hicks; Jasmin Divers; Carl D Langefeld; Steven C Hunt
Journal:  Am J Nephrol       Date:  2009-01-20       Impact factor: 3.754

View more
  26 in total

1.  The new era of APOL1-associated glomerulosclerosis.

Authors:  Barry I Freedman; Carl D Langefeld
Journal:  Nephrol Dial Transplant       Date:  2012-02-02       Impact factor: 5.992

Review 2.  Target organ damage in African American hypertension: role of APOL1.

Authors:  Barry I Freedman; Mariana Murea
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

3.  Interethnic Variation in Lipid Profiles: Implications for Underidentification of African-Americans at risk for Metabolic Disorders.

Authors:  Amy R Bentley; Charles N Rotimi
Journal:  Expert Rev Endocrinol Metab       Date:  2014-01-10

4.  APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.

Authors:  Orlando M Gutiérrez; Suzanne E Judd; Marguerite R Irvin; Degui Zhi; Nita Limdi; Nicholette D Palmer; Stephen S Rich; Michèle M Sale; Barry I Freedman
Journal:  Nephrol Dial Transplant       Date:  2015-07-06       Impact factor: 5.992

Review 5.  Mechanisms of Injury in APOL1-associated Kidney Disease.

Authors:  Lijun Ma; Jasmin Divers; Barry I Freedman
Journal:  Transplantation       Date:  2019-03       Impact factor: 4.939

Review 6.  APOL1 and nephropathy progression in populations of African ancestry.

Authors:  Barry I Freedman
Journal:  Semin Nephrol       Date:  2013-09       Impact factor: 5.299

7.  The kidney and lipids: preface.

Authors:  Bertram Kasiske; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2014-04       Impact factor: 2.801

8.  Kidney function is associated with an altered protein composition of high-density lipoprotein.

Authors:  Katya B Rubinow; Clark M Henderson; Cassianne Robinson-Cohen; Jonathan Himmelfarb; Ian H de Boer; Tomas Vaisar; Bryan Kestenbaum; Andrew N Hoofnagle
Journal:  Kidney Int       Date:  2017-07-26       Impact factor: 10.612

Review 9.  Hypertension and chronic kidney disease: controversies in pathogenesis and treatment.

Authors:  J L Pirkle; B I Freedman
Journal:  Minerva Urol Nefrol       Date:  2013-03       Impact factor: 3.720

10.  JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy.

Authors:  Jasmin Divers; Marina Núñez; Kevin P High; Mariana Murea; Michael V Rocco; Lijun Ma; Donald W Bowden; Pamela J Hicks; Mitzie Spainhour; David A Ornelles; Steven B Kleiboeker; Kara Duncan; Carl D Langefeld; Jolyn Turner; Barry I Freedman
Journal:  Kidney Int       Date:  2013-05-15       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.